. Neurophage, . Merck, . Roche, . Novartis, . Lundbeck et al., Grant: P20GM109025) BD reports having received consultancy fees from Eli Lilly and Company and Boehringer-Ingelheim; and research funding for his Institution from Roche and Fondation Merck Avenir LF reports receiving honoraria or consultation fees from Avid-Eli Lilly and Company Schering-Plough, Schwabe Pharma, TAD Pharma, and Takeda; and receiving grants from Piramal and Novartis. CRJ reports having provided consulting services for Eli Lilly and Company; owning stock in Johnson and Johnson; and receiving research funding from the) and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation. RWJ reports honoraria and/or consultation fees from AC Immune Roche; and his Institute has received grants for clinical trials from AC Immune JCM reports that neither he nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company; reports participating in the execution of trials of antidementia drugs from Eli Lilly and Company, Biogen, and Janssen; reports serving as a consultant for Eli Lilly and Company; reports receiving research support from Eli Lilly/Avid Radiopharmaceuticals; and reports receiving funding by NIH grants, Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests PSA reports beingP50AG005681; P01AG003991; P01AG026276, and UF01AG032438). RS reports receiving research funding from the National Institute on Aging, the Alzheimer's Association, Fidelity Biosciences, and several philanthropic organizations, Eli Lilly and Co., and Janssen Pharmaceuticals; and has served as a paid consultant to Abbvie Sanofi. SAD, BRM, and JR report being full-time employees and minor stockholders of Eli Lilly and Company. PS reports having acquired grant support from GE Healthcare, Danone Research, Piramal, and MERCK; having received in the past 2 years consultancy/speaker fees (paid to the institution) from Eli Lilly and Company, 11378.

E. Lilly, . Company, I. Indianapolis, U. , E. Lilly et al., The Netherlands. 11 Institute for Memory and Alzheimer's Disease (IM2A) and ICM

H. Essay, A hundred years of Alzheimer's disease research, Neuron, vol.52, pp.3-13, 2006.

G. Glenner, C. Wong, V. Quaranta, and E. Eanes, The Nature and Pathogenesis of the Amyloid Deposits in Alzheimer???s Disease, Appl Pathol, vol.2, pp.357-69, 1984.
DOI : 10.1007/978-94-009-4309-4_24

J. Brion, H. Passareiro, J. Nunez, and J. Flament-durand, Mise en evidence de la immunologique de la protein tau au lesions de degeneresescence neurofibrillaire de la maladie, Arch Biol (Brux), vol.95, pp.229-264, 1985.

J. Cummings, P. Aisen, B. Dubois, L. Frölich, J. Jr et al., Drug development in Alzheimer???s disease: the path to 2025, Alzheimer's Research & Therapy, vol.22, issue.1, pp.10-1186, 2016.
DOI : 10.1016/j.jalz.2016.04.008

D. Hardy and J. Selkoe, The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics, Science, vol.297, issue.5580, pp.353-359, 2002.
DOI : 10.1126/science.1072994

J. Price, M. Jr, D. Buckles, V. Roe, C. Xiong et al., Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease, Neurobiology of Aging, vol.30, issue.7, pp.1026-1062, 2009.
DOI : 10.1016/j.neurobiolaging.2009.04.002

S. Vos, C. Xiong, P. Visser, M. Jasielec, J. Hassenstab et al., Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study, The Lancet Neurology, vol.12, issue.10, pp.957-65, 2013.
DOI : 10.1016/S1474-4422(13)70194-7
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904678

H. Braak and E. Braak, Neuropathological stageing of Alzheimer-related changes, Acta Neuropathologica, vol.80, issue.4, pp.239-59, 1991.
DOI : 10.1007/978-3-642-70644-8_2

T. Gomez-isla, R. Hollister, H. West, S. Mui, J. Growdon et al., Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease, Annals of Neurology, vol.46, issue.suppl, pp.17-24, 1997.
DOI : 10.1002/ana.410300206

D. Strooper, B. Karran, and E. , The Cellular Phase of Alzheimer???s Disease, Cell, vol.164, issue.4, pp.603-618, 2016.
DOI : 10.1016/j.cell.2015.12.056

J. Raskin, J. Cummings, J. Hardy, K. Schuh, and R. Dean, Neurobiology of Alzheimer???s Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions, Current Alzheimer Research, vol.12, issue.8, pp.712-734, 2015.
DOI : 10.2174/1567205012666150701103107
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384474

L. Ittner and J. Götz, Amyloid-?? and tau ??? a toxic pas de deux in Alzheimer's disease, Nature Reviews Neuroscience, vol.37, issue.2, pp.65-72, 2011.
DOI : 10.1016/j.nbd.2009.09.004

T. Arendt, J. Stieler, and M. Holzer, Tau and tauopathies, Brain Research Bulletin, vol.126, pp.238-92, 2016.
DOI : 10.1016/j.brainresbull.2016.08.018

J. Crary, J. Trojanowski, and J. Schneider, Primary age-related tauopathy (PART): a common pathology associated with human aging, Acta Neuropathologica, vol.35, issue.Suppl 2, pp.755-66, 2014.
DOI : 10.1016/j.neurobiolaging.2013.10.074
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4257842

K. Jellinger, I. Alafuzoff, J. Attems, T. Beach, N. Cairns et al., PART, a distinct tauopathy, different from classical sporadic Alzheimer disease, Acta Neuropathologica, vol.23, issue.Suppl 2, pp.757-62, 2015.
DOI : 10.1046/j.1440-1789.2003.00522.x
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534004

R. Sperling, P. Aisen, L. Beckett, D. Bennett, S. Craft et al., Toward defining the preclinical stages of Alzheimer???s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia, vol.7, issue.3, pp.280-92, 2011.
DOI : 10.1016/j.jalz.2011.03.003

E. Mormino, R. Betensky, T. Hedden, A. Schultz, A. Ward et al., Amyloid and APOE ??4 interact to influence short-term decline in preclinical Alzheimer disease, Neurology, vol.82, issue.20, pp.1760-1767, 2014.
DOI : 10.1212/WNL.0000000000000431
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035706

Y. Stern, Cognitive reserve in ageing and Alzheimer's disease, The Lancet Neurology, vol.11, issue.11, pp.1006-1018, 2012.
DOI : 10.1016/S1474-4422(12)70191-6

T. Ngandu, J. Lehtisalo, A. Solomon, E. Levälahti, S. Ahtiluoto et al., A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial, The Lancet, vol.385, issue.9984, pp.2255-63, 2015.
DOI : 10.1016/S0140-6736(15)60461-5

M. Rusanen, M. Kivipelto, Q. Jr, C. Zhou, J. Whitmer et al., Heavy Smoking in Midlife and Long-term Risk of Alzheimer Disease and Vascular Dementia, Archives of Internal Medicine, vol.171, issue.4, pp.333-342, 2011.
DOI : 10.1001/archinternmed.2010.393

A. Solomon, F. Mangialasche, E. Richard, S. Andrieu, D. Bennett et al., Advances in the prevention of Alzheimer's disease and dementia, Journal of Internal Medicine, vol.293, issue.Suppl. 3, pp.229-50, 2014.
DOI : 10.1001/jama.293.18.2257

B. Dubois, H. Feldman, C. Jacova, H. Hampel, J. Molinuevo et al., Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria, The Lancet Neurology, vol.13, issue.6, pp.614-29757, 2014.
DOI : 10.1016/S1474-4422(14)70090-0

J. Jr, C. Wiste, H. Vemuri, P. Weigand, S. Senjem et al., Alzheimer's Disease Neuroimaging Initiative. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease, Brain, vol.133, pp.3336-3384, 2010.

J. Jr, C. Knopman, D. Jagust, W. Petersen, R. Weiner et al., Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers, Lancet Neurol, vol.12, pp.207-223, 2013.

R. Bateman, C. Xiong, T. Benzinger, A. Fagan, A. Goate et al., Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease, New England Journal of Medicine, vol.367, issue.9, pp.795-804, 2012.
DOI : 10.1056/NEJMoa1202753
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474597

T. Benzinger, T. Blazey, J. Jr, C. Koeppe, R. Su et al., Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease, Proceedings of the National Academy of Sciences, vol.53, issue.3, pp.4502-4511, 2013.
DOI : 10.2307/2533558

A. Fleisher, K. Chen, Y. Quiroz, L. Jakimovich, G. Gomez et al., Associations Between Biomarkers and Age in the Presenilin 1 E280A Autosomal Dominant Alzheimer Disease Kindred, JAMA Neurology, vol.72, issue.3, pp.316-340, 2015.
DOI : 10.1001/jamaneurol.2014.3314

I. Van-rossum, P. Visser, D. Knol, W. Van-der-flier, C. Teunissen et al., Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease, J Alzheimers Dis, vol.29, pp.319-346, 2012.

R. Ossenkoppele, D. Schonhaut, M. Schöll, S. Lockhart, N. Ayakta et al., Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer???s disease, Brain, vol.139, issue.5, pp.1551-67, 2016.
DOI : 10.1093/brain/aww027
URL : http://doi.org/10.1093/brain/aww027

V. Villemagne, S. Burnham, P. Bourgeat, B. Brown, K. Ellis et al., Amyloid ?? deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study, The Lancet Neurology, vol.12, issue.4, pp.357-67, 2013.
DOI : 10.1016/S1474-4422(13)70044-9

R. Ossenkoppele, B. Cohn-sheehy, L. Joie, R. Vogel, J. Möller et al., Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease, Human Brain Mapping, vol.41, issue.11, pp.4421-4458, 2015.
DOI : 10.1016/j.neuron.2012.03.004

W. Jansen, R. Ossenkoppele, D. Knol, B. Tijms, P. Scheltens et al., Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia, JAMA, vol.313, issue.19, pp.1924-1962, 2015.
DOI : 10.1001/jama.2015.4668

E. Corder, A. Saunders, W. Strittmatter, D. Schmechel, P. Gaskell et al., Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families, Science, vol.261, issue.5123, pp.921-924, 1993.
DOI : 10.1126/science.8346443

M. Chartier-harlin, M. Parfitt, S. Legrain, J. Pérez-tur, T. Brousseau et al., Apolipoprotein E, ??4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region, Human Molecular Genetics, vol.3, issue.4, pp.569-74, 1994.
DOI : 10.1093/hmg/3.4.569

R. Petersen, H. Wiste, S. Weigand, W. Rocca, R. Roberts et al., Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community, JAMA Neurology, vol.73, issue.1, pp.85-92481, 2016.
DOI : 10.1001/jamaneurol.2015.3098

D. Johnson, M. Storandt, J. Morris, and J. Galvin, Longitudinal Study of the Transition From Healthy Aging to Alzheimer Disease, Archives of Neurology, vol.66, issue.10, pp.1254-1263, 2009.
DOI : 10.1001/archneurol.2009.158

M. Donohue, R. Sperling, D. Salmon, D. Rentz, R. Raman et al., The Preclinical Alzheimer Cognitive Composite, JAMA Neurology, vol.71, issue.8, pp.961-70, 2014.
DOI : 10.1001/jamaneurol.2014.803
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4439182

F. Jessen, Subjective and objective cognitive decline at the pre-dementia stage of Alzheimer???s disease, European Archives of Psychiatry and Clinical Neuroscience, vol.9, issue.S1, pp.3-7, 2014.
DOI : 10.1371/journal.pone.0100812

H. Liu-seifert, E. Siemers, K. Price, B. Han, K. Selzler et al., Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer???s Disease, Journal of Alzheimer's Disease, vol.61, issue.1, pp.205-219, 2015.
DOI : 10.1001/archneur.61.4.556

B. Dubois, H. Feldman, C. Jacova, S. Dekosky, P. Barberger-gateau et al., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS???ADRDA criteria, The Lancet Neurology, vol.6, issue.8, pp.734-780, 2007.
DOI : 10.1016/S1474-4422(07)70178-3

M. Albert, S. Dekosky, D. Dickson, B. Dubois, H. Feldman et al., The diagnosis of mild cognitive impairment due to Alzheimer???s disease: Recommendations from the National Institute on Aging-Alzheimer???s Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia, vol.7, issue.3, pp.270-279, 2011.
DOI : 10.1016/j.jalz.2011.03.008

G. Mckhann, D. Knopman, H. Chertkow, B. Hyman, C. Jack et al., The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Synergistic effect of ?-amyloid and neurodegeneration on cognitive decline in clinically normal individuals, JAMA Neurol, vol.71, pp.1379-85, 2014.

M. Wagner, S. Wolf, F. Reischies, M. Daerr, S. Wolfsgruber et al., Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease, Neurology, vol.78, issue.6, pp.379-86, 2012.
DOI : 10.1212/WNL.0b013e318245f447

K. Jekel, M. Damian, C. Wattmo, L. Hausner, R. Bullock et al., Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review, Alzheimer's Research & Therapy, vol.8, issue.Suppl 2, p.17, 2015.
DOI : 10.2147/CIA.S40087

J. Jr, C. Bennett, D. Blennow, K. Carrillo, M. Feldman et al., An unbiased descriptive classification scheme for Alzheimer disease biomarkers, Neurology, vol.87, pp.539-586, 2016.

B. Dubois, H. Hampel, H. Feldman, P. Scheltens, P. Aisen et al., Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria, Alzheimer's & Dementia, vol.12, issue.3, pp.292-323, 2015.
DOI : 10.1016/j.jalz.2016.02.002

S. Arneri?, R. Batrla-utermann, L. Beckett, T. Bittner, K. Blennow et al., Cerebrospinal Fluid Biomarkers for Alzheimer???s Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team, Journal of Alzheimer's Disease, vol.7, issue.Suppl, pp.19-35, 2017.
DOI : 10.3233/JAD-160573

G. Chételat, L. Joie, R. Villain, N. Perrotin, A. De-la-sayette et al., Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease, NeuroImage: Clinical, vol.2, pp.356-65, 2013.
DOI : 10.1016/j.nicl.2013.02.006

K. Johnson, A. Schultz, R. Betensky, J. Becker, J. Sepulcre et al., Tau positron emission tomographic imaging in aging and early Alzheimer disease, Annals of Neurology, vol.128, issue.3 pt 1, pp.110-119, 2016.
DOI : 10.1007/s00401-014-1349-0
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4738026

E. Siemers, K. Sundell, C. Carlson, M. Case, G. Sethuraman et al., Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients, Alzheimer's & Dementia, vol.12, issue.2, pp.110-130, 2016.
DOI : 10.1016/j.jalz.2015.06.1893
URL : http://doi.org/10.1016/j.jalz.2015.06.1893

R. Petersen, P. Aisen, B. Boeve, Y. Geda, R. Ivnik et al., Mild cognitive impairment due to Alzheimer disease in the community, Ann Neurol, vol.74, pp.199-208, 2013.

D. Galasko, D. Bennett, M. Sano, C. Ernesto, R. Thomas et al., An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's disease Cooperative Study Alzheimer's Disease and Associated Disorders, pp.33-42, 1997.

R. Hamel, S. Köhler, N. Sistermans, T. Koene, Y. Pijnenburg et al., The trajectory of cognitive decline in the pre-dementia phase in memory clinic visitors: findings from the 4C-MCI study, Psychological Medicine, vol.34, issue.07, pp.1509-1528, 2015.
DOI : 10.1016/S1474-4422(06)70550-6

S. Walsh, R. Raman, K. Jones, and P. Aisen, ADCS Prevention Instrument Project: The Mail-In Cognitive Function Screening Instrument (MCFSI), Alzheimer Disease & Associated Disorders, vol.20, issue.Supplement 3, pp.170-178, 2006.
DOI : 10.1097/01.wad.0000213879.55547.57

D. Marson, S. Sawrie, S. Snyder, B. Mcinturff, T. Stalvey et al., Assessing Financial Capacity in Patients With Alzheimer Disease, Archives of Neurology, vol.57, issue.6, pp.877-84, 2000.
DOI : 10.1001/archneur.57.6.877

H. Buschke, G. Kuslansky, M. Katz, W. Stewart, M. Sliwinski et al., Lipton RB Screening for dementia with the Memory Impairment Screen H, Neurology, vol.52, 1999.

E. Grober and H. Buschke, Genuine memory deficits in dementia, Developmental Neuropsychology, vol.8, issue.1, pp.13-36, 1987.
DOI : 10.1080/01688638308401157

J. Galvin, C. Roe, K. Powlishta, M. Coats, S. Muich et al., The AD8: A brief informant interview to detect dementia, Neurology, vol.65, issue.4, pp.559-64, 2005.
DOI : 10.1212/01.wnl.0000172958.95282.2a

J. Wang, V. Logovinsky, S. Hendrix, S. Stanworth, C. Perdoma et al., ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials, Journal of Neurology, Neurosurgery & Psychiatry, vol.2, issue.9, pp.993-1002, 2016.
DOI : 10.1001/archneur.64.9.1323
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013117

H. Brodaty, D. Pond, N. Kemp, G. Luscombe, L. Harding et al., The GPCOG: A New Screening Test for Dementia Designed for General Practice, Journal of the American Geriatrics Society, vol.44, issue.3, pp.530-534, 2002.
DOI : 10.1093/geront/9.3_Part_1.179

S. Borson, J. Scanlan, M. Brush, P. Vitaliano, and A. Dokmak, The Mini-Cog: a cognitive ?vital signs? measure for dementia screening in multi-lingual elderly, International Journal of Geriatric Psychiatry, vol.12, issue.11, pp.1021-1028, 2000.
DOI : 10.1002/(SICI)1099-1166(199701)12:1<101::AID-GPS469>3.0.CO;2-R

C. Randolph, M. Tierney, E. Mohr, and T. Chase, The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Preliminary Clinical Validity, Journal of Clinical and Experimental Neuropsychology (Neuropsychology, Development and Cognition: Section A), vol.20, issue.3, pp.310-319, 1988.
DOI : 10.1076/jcen.20.3.310.823

B. Dubois, J. Touchon, F. Portet, P. Ousset, B. Vellas et al., The " 5-words " : a simple and sensitive test for the diagnosis of Alzheimer's disease, Presse Med, vol.31, pp.1696-1705, 2002.

E. Mormont and J. Jamart, Validity of the Five-Word Test for the Evaluation of Verbal Episodic Memory and Dementia in a Memory Clinic Setting, Journal of Geriatric Psychiatry and Neurology, vol.163, issue.3, pp.78-84, 2012.
DOI : 10.1016/S0035-3787(07)90404-X

R. Elwood, The California Verbal Learning Test: Psychometric characteristics and clinical application, Neuropsychology Review, vol.99, issue.Suppl., pp.173-201, 1995.
DOI : 10.1176/ajp.152.1.137

Z. Nasreddine, N. Phillips, V. Bédirian, S. Charbonneau, V. Whitehead et al., The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment, Journal of the American Geriatrics Society, vol.48, issue.4, pp.695-704, 2005.
DOI : 10.1212/WNL.52.2.231

P. Noone, Addenbrooke???s Cognitive Examination-III, Occupational Medicine, vol.65, issue.5, pp.418-438, 2015.
DOI : 10.1093/occmed/kqv041

M. Folstein, S. Folstein, and P. Mchugh, ???Mini-mental state???, Journal of Psychiatric Research, vol.12, issue.3, pp.189-98, 1975.
DOI : 10.1016/0022-3956(75)90026-6

W. Rosen, R. Mohs, and K. Davis, A new rating scale for Alzheimer's disease, Am J Psychiatry, vol.41, pp.1356-64, 1984.

L. Berg, Clinical Dementia Rating (CDR) Psychopharm Bull, pp.637-646, 1988.

J. Saxton and A. Swihart, Neuropsychological assessment of the severely impaired elderly patient, Clin Geriatr Med, vol.5, pp.531-574, 1989.